Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies (Q33183188)

23 July 2017

title

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies (English)

1 reference

23 July 2017

1 reference

1 reference

Gelderblom H

1

1 reference

23 July 2017

Loos WJ

2

1 reference

23 July 2017

Verweij J

3

1 reference

23 July 2017

van der Burg ME

4

1 reference

23 July 2017

de Jonge MJ

5

1 reference

23 July 2017

Brouwer E

6

1 reference

23 July 2017

Nooter K

7

1 reference

23 July 2017

Stoter G

8

1 reference

23 July 2017

Sparreboom A

9

1 reference

23 July 2017

language of work or name

1 reference

1 January 2002

1 reference

European Journal of Cancer

23 July 2017

published in

1 reference

23 July 2017

volume

38

1 reference

23 July 2017

issue

1

1 reference

23 July 2017

page(s)

205-213

1 reference

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Weekly high-dose cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Isolation of mast cells from rabbit lung and liver: comparison of histamine release induced by the hypnotics Althesin and propanidid.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Study of histamine release induced by acute administration of antitumor agents in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

The influence of histamine on precursors of granulocytic leukocytes in murine bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

The influence of histamine at various concentrations on the cell cycle state of hematopoietic stem cells (cfu‐s)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

GM-CSF in association with IL-1 triggers day-8 CFU-S into cell cycle: Role of histamine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

New role for histamine in interleukin-3-induced proliferation of hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Reversal of multidrug resistance by surfactants

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Biodistribution and PDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Properties of cremophor EL micelles probed by fluorescence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900348-3

7 January 2021

10.1016/S0959-8049(01)00348-3

Identifiers

DOI

1 reference

23 July 2017

1 reference